SGLT2 Inhibitors for Heart Failure and Kidney Disease: When and Why I Prescribe Them

About a decade ago, if you'd told me I'd be prescribing a diabetes drug to my heart failure patients who don't have diabetes, I would have been skeptical. But that's exactly what I do now, multiple times every week. SGLT2 inhibitors started as medications for type 2 diabetes, but the evidence in heart failure and chronic kidney disease has been so strong that they've become foundational drugs in my preventive and therapeutic cardiology practice. This article covers what these drugs actually do, why the data changed my prescribing habits, who benefits most, and what side effects and costs you need to know about.

The story of SGLT2 inhibitors is a reminder that good science sometimes takes us in unexpected directions. A medication class designed to help with blood sugar control ended up revolutionizing how we treat heart failure and protect kidney function. That's not hyperbole, it's the real outcome of major randomized trials over the past five years.

If your cardiologist has mentioned one of these drugs, or if you're curious about whether you might be a candidate, read on. These medications work through a surprising mechanism, and understanding that mechanism helps explain why they work in conditions that seem unrelated to diabetes.

What SGLT2 Inhibitors Are and How They Work

The name SGLT2 refers to a protein in your kidneys called sodium-glucose co-transporter 2. Here's the physiology. Your blood is filtered continuously at the glomerulus, the working unit of the kidney. That filtered fluid contains glucose, but normally almost all of it gets reabsorbed back into the bloodstream by the proximal tubule through transporters like SGLT2. You don't spill glucose into your urine under normal circumstances.

SGLT2 inhibitors block that reabsorption. They cause glucosuria, meaning glucose spills into your urine instead of being reclaimed. That might sound wasteful, and in a sense it is. You're losing calories as glucose in the urine. But it turns out that the downstream effects of that simple change have profound benefits for the heart and the kidneys.

The drugs in this class that I prescribe most often are empagliflozin (brand name Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro). All of them work through the same SGLT2 mechanism, though they differ in potency, tolerability, and the body of evidence supporting different uses.

The physiological magic happens when you step back and think about osmotic pressure. When glucose is present in the tubular fluid, it pulls water with it. That water can't be reabsorbed passively because there's solute (glucose) holding it there. The result is osmotic diuresis, a shift in where your body retains and loses fluid. You lose glucose and water in urine. Your blood volume shifts slightly. Your kidneys respond to that change in hemodynamics through a feedback system called the tubuloglomerular feedback mechanism, which relaxes the vasoconstriction of the afferent arteriole and reduces intraglomerular pressure. Lower pressure in the filtering unit means less proteinuria and less progressive kidney damage. Meanwhile, your cardiac preload drops slightly, which helps decompress the heart in heart failure. That's why the same drug works in both heart failure and kidney disease.

The Major Trials That Changed Everything

The evidence base for SGLT2 inhibitors is unusually robust for cardiovascular medication. Let me walk through the key trials because they're the reason I prescribe these drugs so widely.

EMPA-REG OUTCOME (2015) studied empagliflozin in patients with type 2 diabetes and established cardiovascular disease. The primary result was a 14 percent reduction in cardiovascular death and nonfatal MI. But the more striking finding was a 35 percent reduction in hospitalizations for heart failure, even in patients without a prior heart failure diagnosis. That result was unexpected and opened the door to studying these drugs in heart failure patients without diabetes.

DAPA-HF (2019) took dapagliflozin into heart failure with reduced ejection fraction (HFrEF). Patients with HFrEF, with or without diabetes, received either dapagliflozin or placebo on top of standard HF therapy. The study was stopped early because the drug was so clearly beneficial. Dapagliflozin reduced the composite of cardiovascular death or worsening heart failure hospitalizations by 26 percent. The benefit came quickly, within weeks of starting the drug.

EMPEROR-Reduced (2020) tested empagliflozin in HFrEF patients. Similar design, similar result. A 25 percent reduction in the composite of cardiovascular death or heart failure hospitalization. Again, benefit within weeks.

EMPEROR-Preserved (2021) expanded the indication to heart failure with preserved ejection fraction (HFpEF), the form of heart failure that accounts for roughly half of all HF cases. Many older patients with hypertension and stiffened left ventricles end up with HFpEF, and for decades we had no drugs that improved outcomes in this population. Empagliflozin reduced the composite endpoint by 21 percent. It wasn't as dramatic as in HFrEF, but it was real and meaningful.

DELIVER (2022) looked at dapagliflozin in mildly reduced and preserved ejection fraction heart failure, the range of 40 to 49 percent ejection fraction. Again, benefit was demonstrated, a 18 percent reduction in the primary outcome.

On the kidney side, DAPA-CKD and EMPA-KIDNEY both showed that SGLT2 inhibitors slow the progression of chronic kidney disease, whether or not the patient has diabetes. CREDENCE showed benefit in diabetic kidney disease specifically.

What strikes me about this evidence is the consistency and the speed of benefit. Within weeks, not months. And the benefit cuts across ejection fraction categories, across diabetic and nondiabetic populations, and across multiple drugs in the class.

Indications and Who Benefits Most

Based on this evidence, here's how I think about SGLT2 inhibitors in my practice:

Heart failure with reduced ejection fraction (HFrEF). This is where the evidence is strongest and where I prescribe most aggressively. Any patient with HFrEF, diabetic or not, is a candidate unless there's a contraindication. I typically start one as part of the foundational regimen, alongside an ACE inhibitor or ARB, a beta-blocker, an aldosterone antagonist, and an ARNI if appropriate.

Heart failure with preserved ejection fraction (HFpEF). The benefit here is more modest than in HFrEF, but it's still real and statistically significant. Many of my older patients with hypertension and HFpEF are on an SGLT2 inhibitor.

Chronic kidney disease. SGLT2 inhibitors slow the decline in kidney function and reduce proteinuria. I prescribe them in patients with diabetic and nondiabetic CKD, especially if there's significant albuminuria. In many cases, these drugs are cardioprotective and renoprotective simultaneously.

Type 2 diabetes with cardiovascular risk. Even without documented heart failure, patients with T2DM and established atherosclerosis, prior MI, or significant multiple risk factors benefit from an SGLT2 inhibitor. The cardiovascular risk reduction is substantial.

Prevention in high-risk populations. Some of my patients with hypertension, obesity, and strong family histories of early heart disease are on an SGLT2 inhibitor partly for its modest weight loss and blood pressure benefits and partly because I expect that the heart protective effect might prevent or delay frank heart disease.

How Much Benefit, In Numbers

Let me translate the trial data into numbers that matter in clinic. A patient with HFrEF on dapagliflozin has roughly a 26 percent lower risk of cardiovascular death or hospitalization for worsening heart failure compared to someone on placebo. That sounds abstract, so let me put it another way. If I start 10 HFrEF patients on dapagliflozin, I expect to prevent approximately one hospitalization or cardiovascular death over about 18 months compared to not using it, assuming they all stay on the drug and their underlying disease severity is similar to the trial population.

The hospitalization reduction is particularly valuable because HF hospitalizations are awful for patients. You spend days in the hospital, you're exhausted afterward, and there's real risk of complications. If I can reduce the chance of that happening, that matters even if the absolute numbers sound modest.

In kidney disease, the number needed to treat to prevent one doubling of serum creatinine or progression to end-stage renal disease over several years is also in the range of 10 to 20, depending on baseline severity and the specific trial. That's significant when you're talking about preserving kidney function over a lifetime.

The benefit comes remarkably quickly. In DAPA-HF, significant separation of the curves occurred within the first 4 weeks. This isn't a drug that takes months to work. Most patients feel better, with less dyspnea and orthopnea, within days to weeks of starting.

Renal Protection and Why the Kidney Benefits Matter

The kidney protection story is one of the most compelling reasons I reach for these drugs. Chronic kidney disease and heart failure are intertwined. Kidney disease increases your risk of heart disease, and heart disease damages the kidneys. It's a vicious cycle. Breaking that cycle at both ends is powerful.

SGLT2 inhibitors reduce proteinuria substantially, sometimes by 30 to 50 percent. They lower intraglomerular pressure through the tubuloglomerular feedback mechanism I described earlier. They reduce inflammation and fibrosis. The net result is that they slow kidney disease progression in patients with diabetic kidney disease, nondiabetic CKD, and even in patients with CKD and heart failure together.

In DAPA-CKD, dapagliflozin cut the risk of a 50 percent decline in eGFR, end-stage renal disease, or renal death by approximately 39 percent in patients with CKD and albuminuria, most of whom didn't have diabetes. That's a transformative result for a disease that historically had no great options beyond tight blood pressure control and ACE inhibitors.

I counsel my CKD patients that this drug might help preserve kidney function for years or even decades. That conversation changes lives because kidney disease progression feels inevitable to many patients once they've been diagnosed.

Who Shouldn't Take SGLT2 Inhibitors

SGLT2 inhibitors are generally well tolerated, but there are contraindications and cautions.

History of diabetic ketoacidosis. Patients who've had DKA in the past should typically not take SGLT2 inhibitors. The risk of recurrence is higher, and euglycemic DKA (below) is a potential concern.

Type 1 diabetes. SGLT2 inhibitors are not approved for type 1 diabetes, and there's a real risk of euglycemic DKA. Even though research is ongoing, this remains a contraindication in routine practice.

Severe renal impairment. Most SGLT2 inhibitors require a baseline eGFR of at least 20 to 30 mL/min/1.73m2 to be effective, depending on the specific agent. Below that threshold, the drug loses its glucose-spilling mechanism because the kidneys simply aren't filtering enough glucose.

Recent amputation or high risk of lower-limb amputation. Canagliflozin specifically carries an FDA warning about amputation risk. This came from the CANVAS trial, where there was an increased risk of lower-limb amputation compared to placebo. It's rare, but it's serious. I'm more cautious with canagliflozin in patients with diabetic neuropathy, prior amputation, or severe peripheral artery disease.

Active genital infection. These drugs increase genital mycotic infections (see below), so active infection should be treated before starting.

Acute decompensated heart failure or cardiogenic shock. The diuretic effect and reduction in cardiac preload can be problematic in acute decompensation. These drugs are for chronic HF management, not acute hospitalizations.

Side Effects and How to Manage Them

The side effect profile of SGLT2 inhibitors is manageable and often minor, but there are a few that deserve attention.

Genital mycotic infections (yeast infections). This is the most common side effect and it comes directly from the mechanism. You're spilling glucose into the urine, and glucose is a food source for candida. Women experience yeast infections at higher rates, typically in the range of 10 to 20 percent in trials. Men can develop balanitis. I counsel patients to report this early, especially women, because it's easily treated with topical antifungal creams or an oral fluconazole, and the SGLT2 inhibitor doesn't have to be stopped. I also recommend good hygiene, especially for women to wipe front to back and to change out of damp clothes quickly after exercise.

Euglycemic diabetic ketoacidosis (euglycemic DKA). This is rare but serious. It's a form of DKA that occurs without significantly elevated blood glucose. Patients are at higher risk if they have type 1 diabetes, have had prior DKA, are on insulin, are pregnant or recently postpartum, are critically ill, or are undergoing surgery. The symptoms include nausea, vomiting, dyspnea, fatigue, and abdominal pain. If any of these occur, I tell patients to seek immediate care and mention the SGLT2 inhibitor to their doctor. In practice, euglycemic DKA is uncommon enough that it doesn't keep me from using these drugs in appropriate populations, but it's something I watch for.

Volume depletion and hypotension. SGLT2 inhibitors cause mild volume depletion through osmotic diuresis. Some patients experience dizziness or orthostatic hypotension, especially if they're also on diuretics or ACE inhibitors. I often adjust other medications slightly when starting an SGLT2 inhibitor, particularly in older patients on loop diuretics. Volume status usually stabilizes after the first week or two.

Acute kidney injury. This is uncommon but has been reported in patients who are severely volume depleted, dehydrated from illness, or on other medications that affect renal perfusion (NSAIDs, ACE inhibitors in certain settings). I'm cautious in patients with very low eGFR and I ensure they stay well hydrated during acute illness.

Bone fractures. Some SGLT2 inhibitors, particularly canagliflozin, have been associated with small increases in bone fracture risk, especially at the lower limb. The mechanism isn't completely understood. I take this seriously in elderly patients with osteoporosis, but it's not a reason to avoid the drug if the indication is strong.

Fournier's gangrene. This is an extremely rare but life-threatening necrotizing fasciitis of the perineal area. There are only a handful of cases in the literature. It's serious enough that the FDA issued a warning, but statistically it's so uncommon that I don't avoid these drugs because of it. I do counsel patients to seek immediate care if they develop perineal pain, swelling, redness, or drainage.

Overall, most patients tolerate SGLT2 inhibitors very well. The genital infections are managed easily, and serious side effects are quite rare when the drug is used in appropriate populations.

Dosing and How to Start

Dosing varies by agent and indication. Here's what I typically do in clinic.

Empagliflozin. For heart failure, the standard dose is 10 mg once daily. In kidney disease, some data support lower doses like 10 mg every other day in very advanced CKD. For type 2 diabetes, 10 mg daily is standard, though 25 mg is also available.

Dapagliflozin. For heart failure, 10 mg once daily. For kidney disease, also 10 mg daily. This is straightforward dosing.

Canagliflozin. 100 to 300 mg once daily depending on indication and eGFR. I use it less often than empagliflozin or dapagliflozin, partly because of the amputation signal in CANVAS and partly because the data in heart failure is less robust.

Ertugliflozin. 5 or 10 mg once daily. This agent came later and I have less experience prescribing it, so it's often third or fourth line in my practice.

I typically start at the lowest dose, let patients stay on it for a week or two to see how they tolerate it, and then increase to the target dose. Some patients feel better quickly and some take longer to notice a difference. I check electrolytes and kidney function a week or two after starting, especially in older patients or those with baseline renal impairment.

These are all once-daily dosing, which makes them convenient. Adherence is important because the benefit dissipates if the patient stops the drug.

Cost and Insurance Coverage

SGLT2 inhibitors are expensive. A month's supply of brand-name empagliflozin or dapagliflozin costs roughly $300 to $400 out of pocket at retail prices. With insurance, copays vary widely. Some insurers cover them generously under heart failure or kidney disease indications. Others have step-through requirements, meaning your doctor has to show that you've tried and failed an ACE inhibitor or other first-line agent before they'll cover an SGLT2 inhibitor.

Generic versions are starting to appear as patents expire, and that will bring costs down. Empagliflozin has generic availability in some regions. Dapagliflozin generics are on the horizon.

If cost is a barrier, I talk with patients about patient assistance programs. Many drug manufacturers offer free or reduced-cost medications for uninsured or underinsured patients. Eli Lilly, Merck, and Janssen all have programs. I also check GoodRx or other discount programs. Sometimes a mail-order pharmacy or a 90-day supply through insurance is cheaper than retail.

The cost conversation is real and I don't minimize it. But I also frame it this way: if this drug prevents a heart failure hospitalization, that's a several-thousand-dollar savings right there. If it slows kidney disease and delays dialysis, that's tens of thousands of dollars in savings. The upfront cost is high, but the value is often there.

How I Decide Who to Start on an SGLT2 Inhibitor

The decision to prescribe an SGLT2 inhibitor in my clinic isn't formulaic. It depends on several things.

First, I look at the diagnosis. Is this patient a clear indication, like HFrEF? If yes, they're almost always getting an SGLT2 inhibitor unless they have an absolute contraindication. Is it a softer indication, like type 2 diabetes without heart failure or kidney disease? Then I think about other risk factors. Do they have hypertension, obesity, CKD stage 3 or worse, prior MI, or strong family history? The more risk factors, the more likely I'll recommend one.

Second, I look at what else they're already taking. Are they already on an ACE inhibitor or ARB, a beta-blocker, and an aldosterone antagonist? If we have room to add a fourth agent and the indication is strong, I'll do it. Are they already on three or four cardiac medications? Then I'm thinking about drug interactions, pill burden, and adherence. Some patients can't tolerate taking seven pills a day, and I'd rather they be reliably on four good drugs than unreliably on seven.

Third, I think about kidney function. If the eGFR is below 20 or 25, depending on the agent, the drug won't work well. I'm not starting it in stage 5 CKD unless there's a specific new indication that changes that calculus.

Fourth, I ask about symptoms and preferences. Are they interested in adding another medication? Do they have a history of infections that makes them vulnerable to yeast problems? Are they pregnant or planning pregnancy? Is there anything in their social situation that makes adherence unlikely? These conversations matter because a medication that a patient can't or won't take is worthless.

Finally, I consider what new data might have come out. The evidence base continues to grow. SGLT2 inhibitors are being studied in more and more populations, and occasionally surprising findings emerge. I try to stay current with major trials and guidelines.

In practice, the decision usually comes down to this: Does this patient fit the evidence-based indication for an SGLT2 inhibitor, are they medically stable enough to start it safely, and is there no absolute contraindication? If the answer to all three is yes, we usually start it. The benefit-to-risk calculation favors the drug in most of the patients I see.

The Bottom Line

SGLT2 inhibitors have moved from niche diabetes drugs to foundational therapy for heart failure and chronic kidney disease. The evidence is strong, the side effects are manageable for most patients, and the benefits come quickly. I prescribe them regularly in my HFrEF patients, in many of my HFpEF patients, and in patients with CKD with or without diabetes. I do it because the data show they prevent hospitalizations, reduce cardiovascular death, and slow kidney disease progression. Those aren't modest gains, they're meaningful improvements in outcomes.

If you're a patient with heart failure or kidney disease, or if you have type 2 diabetes with cardiovascular risk factors, asking your cardiologist whether an SGLT2 inhibitor is right for you is a reasonable conversation. These drugs have changed my practice and improved outcomes for my patients. They'll continue to be central to how I manage these conditions for years to come.

Frequently Asked Questions

Do SGLT2 inhibitors actually work if you don't have diabetes?

Yes, absolutely. The mechanism works independently of blood sugar. Even patients with normal glucose levels benefit from the diuretic effect, the reduction in blood pressure, the renal protective effects, and the cardiac remodeling benefits. The trials that proved benefit in heart failure and kidney disease included large numbers of patients without diabetes, and the benefit was just as clear as in diabetic patients.

How quickly do they work?

Very quickly. In DAPA-HF, measurable benefit appeared within the first month of treatment. Most patients with heart failure notice improved breathing and less fluid retention within days to weeks. The kidney protective effects take longer to measure but begin immediately at the cellular level. This isn't a drug where you wait months to see if it's helping.

Can I take an SGLT2 inhibitor if I'm on dialysis?

No. Once your kidneys are on dialysis, the drug no longer works because there's no glomerular filtration, so glucose can't spill into urine. SGLT2 inhibitors are meant for patients with some residual kidney function. For dialysis patients with heart failure, other medications are the focus.

What if I have both heart failure and kidney disease?

This is where SGLT2 inhibitors shine. They address both conditions simultaneously. The same mechanisms that protect the heart also protect the kidneys. If you have HF and CKD together, an SGLT2 inhibitor is very likely part of your treatment plan.

Do I need to check my blood sugar more often?

If you have diabetes and are on insulin or other glucose-lowering medication, yes. SGLT2 inhibitors can lower blood glucose, especially in combination with insulin or sulfonylureas. Your doctor may reduce the dose of those other medications. If you're not on diabetes medication, you don't need to check glucose more frequently just because you're on an SGLT2 inhibitor.

Can I stop it when I feel better?

No. These medications work while you're taking them, but the benefit goes away if you stop. Just like blood pressure medication or heart failure medication, the SGLT2 inhibitor is usually a long-term commitment. If you feel better, that's because the drug is working. Stopping it means losing that benefit. Talk to your cardiologist before making any changes to your medication regimen.

Are there any drug interactions I need to worry about?

The main interactions are with other medications that affect blood pressure, kidney function, or volume status. NSAIDs, ACE inhibitors, and diuretics are commonly used together with SGLT2 inhibitors, but your doctor needs to monitor kidney function and blood pressure. There are no major drug-drug interactions with the SGLT2 inhibitors themselves.

What if I'm having surgery?

Talk to your surgeon and cardiologist. There's been some concern about perioperative DKA with SGLT2 inhibitors, so some surgeons ask you to hold the drug for a day or two around the time of surgery. The details depend on the type of surgery and your overall risk profile. Don't stop the drug on your own, but do coordinate with your surgical team.

References

1. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

2. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.

3. Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424.

4. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461.

5. Solomon SD, et al. SGLT2 Inhibitors in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(13):1195-1206.

6. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.

7. Perkovic V, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2023;388(2):117-127.

8. Bakris GL, et al. Finerenone in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med. 2020;383(35):353-362.

9. Mahaffey KW, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. N Engl J Med. 2018;380(4):325-336.

10. Wiviott SD, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317-1326.

11. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Supplement 1).

12. ACC/AHA Guidelines for the Management of Heart Failure. Circulation. 2022;145(18).